Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 2/2011

Open Access 01-04-2011 | Original Paper

Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case–control study

Authors: Monique M. Gerrits, Min Chen, Myrte Theeuwes, Herman van Dekken, Marjolein Sikkema, Ewout W. Steyerberg, Hester F. Lingsma, Peter D. Siersema, Bing Xia, Johannes G. Kusters, C. Janneke van der Woude, Ernst J. Kuipers

Published in: Cellular Oncology | Issue 2/2011

Login to get access

Abstract

Background

Regular colonoscopic surveillance for detection of dysplasia is recommended in longstanding inflammatory bowel disease (IBD), however, its sensitivity is disputed. Screening accuracy may increase by using a biomarker-based surveillance strategy.

Methods

A case-control study was performed to determine the prognostic value of DNA ploidy and p53 in IBD-related neoplasia. Cases with IBD-related colorectal cancer (CRC), detected in our surveillance program between 1985-2008, were selected and matched with two controls, for age, gender, disease characteristics, interval of follow-up, PSC, and previous surgery. Biopsies were assessed for DNA ploidy, p53, grade of inflammation and neoplasia. Progression to neoplasia was analyzed with Cox regression analysis, adjusting for potentially confounding variables.

Results

Adjusting for age, we found statistically significant Hazard ratios (HR) between development of CRC, and low grade dysplasia (HR5.5; 95%CI 2.6-11.5), abnormal DNA ploidy (DNA index (DI) 1.06-1.34, HR4.7; 95%CI 2.9-7.8 and DI>1.34, HR6.6; 95%CI 3.7-11.7) and p53 immunopositivity (HR3.0; 95%CI 1.9-4.7) over time. When adjusting for all confounders, abnormal DNA ploidy (DI 1.06-1.34, HR4.7; 95%CI 2.7-7.9 and DI>1.34, HR5.0; 95%CI 2.5-10.0) and p53 immunopositivity (HR1.7; 95%CI 1.0-3.1) remained statistically significant predictive of neoplasia.

Conclusion

In longstanding IBD, abnormal DNA ploidy and p53 immunopositivity are important risk factors of developing CRC. The yield of surveillance may potentially increase by adding these biomarkers to the routine assessment of biopsies.
Literature
1.
A. Ahmadi, S. Polyak, P.V. Draganov, Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J. Gastroenterol. 15, 61–66 (2009)PubMedCrossRef
2.
F.A. Farraye, R.D. Odze, J. Eaden, S.H. Itzkowitz. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138, 738–745 (2010)
3.
R. Befrits, C. Hammarberg, C. Rubio, E. Jaramillo, B. Tribukait, DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis. Colon Rectum 37, 313–319 (1994). discussion 9–20PubMedCrossRef
4.
S.R. Cairns, J.H. Scholefield, R.J. Steele, M.G. Dunlop, H.J. Thomas, G.D. Evans, J.A. Eaden, M.D. Rutter, W.P. Atkin, B.P. Saunders, A. Lucassen, P. Jenkins, P.D. Fairclough, C.R. Woodhouse, Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59, 666–689 (2010)PubMedCrossRef
5.
M.M. Claessen, M.E. Schipper, B. Oldenburg, P.D. Siersema, G.J. Offerhaus, F.P. Vleggaar, WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance. Cell. Oncol. 32, 303–310 (2010)PubMed
6.
P.D. Collins, C. Mpofu, A.J. Watson, J.M. Rhodes, Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst. Rev. (2006):CD000279
7.
J. Eaden, Review article: colorectal carcinoma and inflammatory bowel disease. Aliment. Pharmacol. Ther. 20, 24–30 (2004)PubMedCrossRef
8.
J.A. Eaden, J.F. Mayberry, Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51, V10–V12 (2002)PubMedCrossRef
9.
J. Eaden, K. Abrams, H. McKay, H. Denley, J. Mayberry, Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J. Pathol. 194, 152–157 (2001)PubMedCrossRef
10.
K. Geboes, R. Riddell, A. Ost, B. Jensfelt, T. Persson, R. Lofberg, A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47, 404–409 (2000)PubMedCrossRef
11.
W. Giaretti, S. Molinu, J. Ceccarelli, C. Prevosto, Chromosomal instability, aneuploidy, and gene mutations in human sporadic colorectal adenomas. Cell. Oncol. 26, 301–305 (2004)PubMed
12.
M. Goetz, M.F. Neurath, Imaging techniques in inflammatory bowel disease: recent trends, questions and answers. Gastroentérol. Clin. Biol. 33, S174–S182 (2009)PubMedCrossRef
13.
R.B. Gupta, N. Harpaz, S. Itzkowitz, S. Hossain, S. Matula, A. Kornbluth, C. Bodian, T. Ullman, Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133, 1099–1105 (2007). quiz 340-1PubMedCrossRef
14.
M. Hage, P.D. Siersema, K.J. Vissers, E.W. Steyerberg, J. Haringsma, E.J. Kuipers, H. van Dekken, Molecular evaluation of ablative therapy of Barrett’s oesophagus. J. Pathol. 205, 57–64 (2005)PubMedCrossRef
15.
D.W. Hedley, M.L. Friedlander, I.W. Taylor, C.A. Rugg, E.A. Musgrove, Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem. 31, 1333–1335 (1983)PubMed
16.
K. Holzmann, M. Weis-Klemm, B. Klump, C.J. Hsieh, F. Borchard, M. Gregor, R. Porschen, Comparison of flow cytometry and histology with mutational screening for p53 and Ki-ras mutations in surveillance of patients with long-standing ulcerative colitis. Scand. J. Gastroenterol. 36, 1320–1326 (2001)PubMedCrossRef
17.
S.P. Hussain, P. Amstad, K. Raja, S. Ambs, M. Nagashima, W.P. Bennett, P.G. Shields, A.J. Ham, J.A. Swenberg, A.J. Marrogi, C.C. Harris, Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60, 3333–3337 (2000)PubMed
18.
S. Itzkowitz, Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J. Clin. Gastroenterol. 36, S70–S74 (2003). discussion S94-6PubMedCrossRef
19.
S.H. Itzkowitz, N. Harpaz, Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126, 1634–1648 (2004)PubMedCrossRef
20.
P. Karlen, R. Lofberg, O. Brostrom, C.E. Leijonmarck, G. Hellers, P.G. Persson, Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am. J. Gastroenterol. 94, 1047–1052 (1999)PubMed
21.
B. Klump, K. Holzmann, A. Kuhn, F. Borchard, M. Sarbia, M. Gregor, R. Porschen, Distribution of cell populations with DNA aneuploidy and p53 protein expression in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 9, 789–794 (1997)PubMed
22.
B.A. Lashner, W.M. Bauer, L.A. Rybicki, J.R. Goldblum, Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. Am. J. Gastroenterol. 98, 1423–1427 (2003)PubMed
23.
C.H. Lim, M.F. Dixon, A. Vail, D. Forman, D.A. Lynch, A.T. Axon, Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 52, 1127–1132 (2003)PubMedCrossRef
24.
R. Lofberg, O. Brostrom, P. Karlen, A. Ost, B. Tribukait, DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 102, 1149–1154 (1992)PubMed
25.
J.W. Nathanson, N.E. Yadron, J. Farnan, S. Kinnear, J. Hart, D.T. Rubin, p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn’s disease. Dig. Dis. Sci. 53, 474–480 (2008)PubMedCrossRef
26.
C. Pohl, A. Hombach, W. Kruis, Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 47, 57–70 (2000)PubMed
27.
D. Ramsoekh, M.E. van Leerdam, M. van Ballegooijen, J.D. Habbema, E.J. Kuipers, Population screening for colorectal cancer: faeces, endoscopes or X-rays? Cell. Oncol. 29, 185–194 (2007)PubMed
28.
D. Ramsoekh, J. Haringsma, J. Poley, P. van Putten, H. van Dekken, E.W. Steyerberg, M.E. van Leerdam, E.J. Kuipers, A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects. Gut 59, 785–793 (2010)PubMedCrossRef
29.
R.H. Riddell, H. Goldman, D.F. Ransohoff, H.D. Appelman, C.M. Fenoglio, R.C. Haggitt, C. Ahren, P. Correa, S.R. Hamilton, B.C. Morson et al., Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 14, 931–968 (1983)PubMedCrossRef
30.
D.J. Robertson, E.R. Greenberg, M. Beach, R.S. Sandler, D. Ahnen, R.W. Haile, C.A. Burke, D.C. Snover, R.S. Bresalier, G. McKeown-Eyssen, J.S. Mandel, J.H. Bond, R.U. Van Stolk, R.W. Summers, R. Rothstein, T.R. Church, B.F. Cole, T. Byers, L. Mott, J.A. Baron, Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 129, 34–41 (2005)PubMedCrossRef
31.
M. Rutter, B. Saunders, K. Wilkinson, S. Rumbles, G. Schofield, M. Kamm, C. Williams, A. Price, I. Talbot, A. Forbes, Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126, 451–459 (2004)PubMedCrossRef
32.
T.V. Shankey, P.S. Rabinovitch, B. Bagwell, K.D. Bauer, R.E. Duque, D.W. Hedley, B.H. Mayall, L. Wheeless, C. Cox, Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 14, 472–477 (1993)PubMedCrossRef
33.
U. Sjoqvist, Dysplasia in ulcerative colitis–clinical consequences? Langenbecks Arch. Surg. 389, 354–360 (2004)PubMedCrossRef
34.
U. Sjoqvist, R. Befrits, S. Soderlund, A. Ost, P. Karlen, B. Tribukait, C. Rubio, P. Rutgeerts, K. Geboes, R. Lofberg, Colorectal cancer in colonic Crohn’s disease–high frequency of DNA-aneuploidy. Anticancer Res. 25, 4393–4397 (2005)PubMed
35.
A. Stallmach, C. Bielecki, C. Schmidt, Malignant transformation in inflammatory bowel disease—surveillance guide. Dig. Dis. 27, 584–590 (2009)PubMedCrossRef
Metadata
Title
Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case–control study
Authors
Monique M. Gerrits
Min Chen
Myrte Theeuwes
Herman van Dekken
Marjolein Sikkema
Ewout W. Steyerberg
Hester F. Lingsma
Peter D. Siersema
Bing Xia
Johannes G. Kusters
C. Janneke van der Woude
Ernst J. Kuipers
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2011
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-010-0006-4

Other articles of this Issue 2/2011

Cellular Oncology 2/2011 Go to the issue

Original Paper

Parametric mapping of immunohistochemically stained tissue sections; a method to quantify the colocalization of tumor markers

Original Paper

In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription

Original Paper

Low frequency of HER2 amplification and overexpression in early onset gastric cancer

Original Paper

Pathology of hereditary breast cancer

Original Paper

Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling

Original Paper

Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits